Translate the text from English to Welsh.



 
It is almost two\-and\-a\-half years since the World Health Organisation declared a global coronavirus pandemic. While we have moved beyond the emergency response to the pandemic in Wales and are beginning to manage the virus and Covid\-19 like other seasonal respiratory illnesses, a large number of people continue to suffer from the long\-term impacts of a Covid\-19 infection – known more commonly as long\-Covid.


We are clear that continuing to support people suffering from and recovering from the long\-term effects of Covid\-19, will be a high priority for us and for the NHS.


We launched the Adferiad programme in June 2021 and have provided £10m to health boards to develop services for people with long\-Covid. In February, I provided an update about the first six\-month review of the programme and said I would review it every six months.  Today the next evaluation report is being published.


I am very grateful to everyone who took part in the review, especially all those who have used and benefitted from the services.


The review finds that the integrated, multi\-professional model of locally delivered rehabilitation services continues to meet the needs of the majority of people with long\-Covid who have accessed these services.


The professional and emotional support provided by staff is highly appreciated, as are the opportunities provided for peer support from other people with long\-Covid. 


But the review has highlighted that these services are not working as well as we would like for everybody. A small number of people felt they could be more tailored to meet their individual needs.


This valuable feedback will help health boards to continue to shape services to ensure people receive the best possible care, treatment and support.


We now know more about long\-Covid than we did six months ago but there are many unanswered questions and things we do not fully understand, including why people improve at different rates; why people experience long\-Covid differently and why people respond to treatments differently. 


As a new condition with many unanswered questions, long\-Covid is also a priority for research. We are working with our UK counterparts to ensure emerging evidence makes a difference to treatment and service provision. We have invested £3m in a new Covid\-19 Evidence Centre to ensure the best available, up\-to\-date and relevant evidence is readily available to health and social care to inform their decision making.


The emerging evidence does suggest that vaccines may provide some protection against and reduce the number of new cases of long\-Covid. As we roll\-out the autumn Covid\-19 booster vaccine, this is one more reason to take\-up the offer of vaccination – for both Covid\-19 and seasonal flu – this winter.


 







Translation:


 
Mae bron i ddwy flynedd a hanner wedi pasio ers i Sefydliad Iechyd y Byd ddatgan pandemig coronafeirws byd\-eang. Er ein bod wedi symud y tu hwnt i’r ymateb argyfwng i’r pandemig yng Nghymru ac yn dechrau ymdrin â’r feirws a Covid\-19 fel unrhyw salwch anadlol tymhorol arall, mae nifer fawr o bobl yn parhau i ddioddef effaith hirdymor haint Covid\-19 – y cyfeirir ato’n fwy cyffredin fel Covid hir.


Rydym wedi nodi’n glir y bydd parhau i gefnogi’r bobl sy’n dioddef o effeithiau hirdymor Covid\-19, ac yn gwella o’r effeithiau hyn, yn flaenoriaeth uchel i ni ac i’r GIG.


Gwnaethom lansio’r rhaglen Adferiad ym mis Mehefin 2021 ac rydym wedi rhoi £10m i fyrddau iechyd ar gyfer datblygu gwasanaethau i bobl gyda Covid hir. Ym mis Chwefror, rhoddais ddiweddariad am adolygiad chwe mis cyntaf y rhaglen a dywedais y byddwn yn adolygu’r rhaglen bob chwe mis. Heddiw mae'r adroddiad gwerthuso nesaf yn cael ei gyhoeddi (Saesneg yn unig).


Rwy’n ddiolchgar iawn i bawb sydd wedi cymryd rhan yn yr adolygiad hwn, yn enwedig y rheini sydd wedi defnyddio’r gwasanaethau ac wedi elwa ohonynt.


Mae’r adolygiad wedi canfod fod y model amlbroffesiynol integredig o wasanaethau adfer a ddarperir yn lleol yn parhau i ddiwallu anghenion y mwyafrif o bobl â Covid hir sydd wedi defnyddio’r gwasanaethau hyn.


Mae’r gefnogaeth broffesiynol ac emosiynol a ddarperir gan staff yn cael ei werthfawrogi’n fawr, yn yr un modd â chyfleoedd i gael cymorth gan bobl eraill â Covid hir. 


Ond mae’r adolygiad wedi nodi nad yw’r gwasanaethau hyn yn gweithio gystal ag yr hoffem ar gyfer pawb. Roedd nifer fach o bobl yn teimlo y gallai’r gwasanaethau fod wedi’u teilwra’n well i ddiwallu eu hanghenion unigol.


Bydd yr adborth gwerthfawr hwn yn helpu byrddau iechyd i gynllunio eu gwasanaethau i sicrhau bod pobl yn cael y gofal, y driniaeth a’r cymorth gorau posibl.


Rydym yn gwybod mwy am Covid hir erbyn hyn nag yr oeddem chwe mis yn ôl, ond mae llawer o gwestiynau heb eu hateb a phethau nad ydym yn eu deall yn iawn, gan gynnwys pam y mae rhai pobl yn gwella yn gyflymach na’i gilydd; pam y mae pobl yn cael Covid hir yn wahanol i’w gilydd a pham y mae pobl yn ymateb i driniaethau’n wahanol.


Fel cyflwr newydd, a llawer o gwestiynau heb eu hateb, mae Covid hir hefyd yn flaenoriaeth ar gyfer ymchwil. Rydym yn gweithio gyda’n cymheiriaid yn y DU i sicrhau y bydd y dystiolaeth sy’n dod i’r amlwg yn gwneud gwahaniaeth i driniaethau ac i ddarpariaeth gwasanaethau. Rydym wedi buddsoddi £3m mewn Canolfan Ymchwil Covid\-19 newydd i sicrhau bod y dystiolaeth orau, mwyaf cyfredol a mwyaf perthnasol ar gael i iechyd a gofal cymdeithasol i lywio eu penderfyniadau.


Mae’r dystiolaeth sy’n dod i’r amlwg yn awgrymu y gallai brechlynnau roi peth amddiffyniad yn erbyn Covid hir, a lleihau nifer yr achosion newydd ohono. Wrth inni gyflwyno brechlynnau atgyfnerthu Covid\-19 yr hydref, dyma un rheswm arall dros fanteisio ar y cynnig o frechlyn – ar gyfer Covid\-19 a’r ffliw tymhorol – y gaeaf hwn.